

# European Multiple Sclerosis Platform

Elisabeth Kasilingam, Managing Director

Brussels, 25<sup>th</sup> February 2019

## **About EMSP**

## WHO WE ARE

- Pan-European NGO
   engaged in advocacy and
   awareness-raising activities
- Offering knowledge and expertise in the field of multiple sclerosis (MS).
- Aiming to improve quality
   of life as well as access to
   treatment, care and
   employment.

### WHAT WE DO

- Campaigning through advocacy & awareness raising;
- Collecting and sharing knowledge and expertise;
- Encouraging research and data collection;

## **OUR NETWORK**

- 41 national MS member societies
- 36 European countries

We work together to ensure that people with MS have a real voice in determining their own priorities.



## **Our Vision & Mission**



# **Our Expertise**

**30 years** of advocacy for people with MS across Europe.



### **Advocacy**

Ensure the voice and influence of people with MS is recognised.

Campaign for equitable access to high quality treatment, services and employment across Europe.



### **Knowledge & Expertise**

Share and promote evidencebased best practice. Foster effective cooperation between people affected with MS, health care professionals, policy decision makers and researchers.



### Research

Encourage and support high quality MS research and international MS research collaboration.
Support the collection, pooling and interrogation of essential MS data across Europe.



# **Priorities 2018/2019**



Empowering MS societies and MSers



Strive for better access to healthcare, treatments and therapies



Progress our flagship projects



Strengthening partnerships



Secretariat capacity building



# **Empowering People with MS**



#EMSP2018



Clinical trials workshop



Baltic states meeting



Young people's network



Comms network



# **Empowering People with MS 2019**

- Annual Conference 10-11<sup>th</sup> May, in Vilnius, Lithuania on Digital health in MS management
- Continued series of workshop on Clinical trials and collaboration with the European Centre for Clinical research training
- Focus on the Balkan region to support the MS societies to address better the challenges faced by the people with MS
- Implementation of the Young People's Network
   2.0





## Access to Better treatment and care



MS Nurse PRO



MS Barometer



Cost-of illness study







**EMA** 



# **Advocacy and Campaigning**














**European MS Platform** @eumsplatform · 7 Jun 2018

Policy Coordinator @AAntonovici presents on the EMSP MS Barometer. We ask our members for their priorities at EU level and national level, to work out together and present to the rest of the attendees. Where is leadership at European level & support at local level. #EMSP2018









# **Access to Employment**



Work and employment have been part of EMSP's work for the past 20 years. In particular, we've looked at ways to break down barriers by showing the real-life issues that people have to deal with. We've been ahead of the curve, working closely with the people who know the issues first hand-people with MS and employers.

MS affects people differently, but there are commonalities. Many people experience a range of symptoms. They include mobility issues, loss of senses (sight, feeling, touch sensitivity) chronic pain, fatigue and cognitive issues to name some of the common types. Allowing for symptom management, people with MS want to stay in work and continue with their careers.





## **Data for Better decisions**



## A PRACTICAL **TOOLKIT**

FOR THE IDENTIFICATION, SELECTION AND MEASUREMENT OF OUTCOMES INCLUDING IN **REAL-WORLD SETTINGS** 

IMI DO→IT DELIVERABLE 2.2



### **MS Data Alliance**

#### Better data for better care for people with MS

#### Mission & Objectives

- Increase data quality through a

#### MSDA academy:

community engagement and awareness raising + support implementation

> - Decrease efforts to find, access and re-use data with a

#### MSDA toolbox:

tools for data discovery and re-use, a federated ecosystem

#### Principles

The MSDA tools can only be used for assessing the feasibility of a study and for conducting research by bona fide research organisations as well as for the objective of discovering new knowledge intended for the public good and to be made publicly accessible (i.e. published)

#### Data sources

- will always have autonomy over which data are made accessible and for which types of research
- will always determine ethical acceptability and scientific validity
- must be transparent about their data

#### Data users

- must adhere to the ethical rules and privacy protection policies of each data source
- may only use the data for the specific agreed research purposes
- must acknowledge the sources of the data they have used, and MSDA



#### People with MS/ patient societies

Increase awareness for the relevance of real-world evidence studie for a better care of people with MS Increase data quality to support patient-centered decision making by

through large, quality-assured datasets



#### Market Authorisation holders/Applicants

Increase data quality (EMA approved) to support drug safety and effectiveness research

using existing, quality-assured data



#### Registry custodians

- . Support implementation strategies of (EMA) guidelines for
- standardised, quality-assured (minimal) datasets Facilitate contact with data science experts and provide help desk services to tackle legal, ethical and technical challenges



#### Health Technology Assessment bodies

- Reduce time and costs to incorporate data from clinical practice in
- Increase awareness to include functional- and patient relevant outcome measures when assessing health technologies



- Promote development of decision support systems for diagnosis. prognosis and treatment
- . Offer education and training in and access to real-world evidence



Push innovation in data science Find, access and analyze big datasets for research purposes Enable collaboration between researchers leading to publications, project applications,

Increase data quality to support development of decision support systems for diagnosis, prognosis and treatment

The MS Data Alliance is an joint initiative lead by Hasselt University and the European Multiple Sclerosis Platform

#### The MSDA project initialisation group:

EMSP, the Universities of Hasselt and Swansea, the University Medical Center Göttingen, the German MS Registry plus Biogen and Celgene as industry voice

### Want more information?

Liesbet.peeters@uhasselt.be



# MS Data Alliance

## **MSDA Academy**



WP2: Community engagement strategy

Dissemination & communication - PR strategy - Nurse PRO training module



WP3: Stakeholder engagement meetings

Meeting 1: Inform stakeholders on MSDA strategy and discuss challenges and opportunities

Meeting 2: MSDA evaluation + future steps



Objective 3: Implementation strategies & standard operating procedures



WP7: MSDA academy workshops

Testimonials - Informed consents - GDPR - minimal data set including MRI outcome - PRO - Quality and interoperability

## **MS Data Alliance**

Better data for better decision making

EMA approved minimal data set and quality standards
Data sharing challenges: towards a federated IT independent data ecosystem



### MSDA Toolbox

Objective 2: Tools for data discovery & sharing



WP4: MSDA CATALOGUE

- FIND YOUR COHORT web-based application that
integrates MS data registries
and cohorts, allowing end-users
to browse meta-data



- DATA HARMONIZATION harmonizing an EMA minimal data set (incl. PRO and MRI data);



WP6: MSDA COHORT EXPLORER
- REQUEST & ANALYZE YOUR DATA -

Enables searching aggregated data, allows requests for data and provides a platform to analyze this data securely.



# **EMSP Joining Forces**













'Empowering people affected by mental ill health'

Call to Action





EU Health Summit, European Brain Council, European Patients' Forum and 7 others





HOME WHO WE ARE EVENTS POLICY REGISTER OF SUPPOR





4.1 Value of Treatment for MS: Early treatment is key to slow disease activity & progression. In addition, reduced exposure to lifestyle factors such as cigarette smoking & low Vit D levels also reported to decrease disease progression. ow.ly/cWxb30keg1A #BringingUsCloser



#### Background

Multiple sciences (MS) as a charact, information, comprising and appreciate disease of the central remost spells (CSIG) in highest contributions and 25°C disease. One 2 million properly have 16 seek and 25°C disease (MS) as a character increasing and state (many larger in larger disease). The intermit of procedure in larger intermit intermiting and state (many larger in larger intermiting and in





## **New Executive Committee**



## **Meet Our Team**



President



Emma Rogan
Project Coordinator



Elisabeth Kasilingam

Managing Director



**Máté László Tagaj**Communications and Membership Officer



Christoph Thalheim

Director External Affairs



Žilvinas Gavėnas



Nora Kriauzaite
Programme Coordinator



Krystalenia Ampreou

Administrative Assistant



# **Industry Partners**

































# **Key Milestones**





# Wishing you a lovely evening!











